PPD Named ‘Best Vaccine CRO of the Year’ in Asia-Pacific
December 02 2021 - 9:00AM
Business Wire
PPD, Inc. (Nasdaq: PPD) was named “Best Vaccine CRO of the Year”
at the Asia-Pacific Vaccine Excellence Awards 2021 for its strong
presence, extensive experience and quality delivery in the
Asia-Pacific (APAC) region.
The award recognizes the contract research organization (CRO)
operating within Asia that has engaged in substantial efforts to
innovate, optimize processes and uphold a high level of efficacy,
quality and safety in vaccine development and manufacturing.
PPD accepted the award during a virtual ceremony at the third
annual Vaccine World Asia Congress 2021, which attracted
hundreds of representatives from Asia's top vaccine and supply
chain companies.
“This vaccine award further exemplifies PPD’s commitment to
provide effective site management and ensure quality delivery,
which has contributed to our industry reputation as a global
leader,” said Les Enterline, senior vice president, global
therapeutic unit head, vaccines. “We continue to leverage
technology and implement best practices to help our customers move
vaccines forward. PPD’s extensive pandemic experience also has
assisted in developing leading approaches to help accelerate
COVID-19 vaccines.”
The Vaccine World Asia Congress is a vaccine-focused platform in
Asia that brings together global partners and regional stakeholders
to leverage partnership opportunities, discuss technological
advancements and spearhead scientific innovation.
PPD continues to expand in APAC to serve local and global
customers, with operations across the region. PPD provides a broad
range of Phase I-IV services in APAC, including clinical
monitoring, project management, regulatory affairs,
pharmacovigilance, data management and patient recruitment.
Earlier this year, PPD opened its new multipurpose laboratory in
Suzhou, China, to support Western and China-based pharmaceutical
and biotech companies managing China research studies. The
67,000-square-foot facility in the Suzhou New District, Jiangsu
Province, offers bioanalytical, biomarker and vaccine laboratory
services to support discovery research and clinical trials across
all phases of pharmaceutical development. The lab also supplements
the company’s Shanghai central lab, which was established in
2015.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our customers and partners include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With more than 30,000 professionals
worldwide, PPD has conducted clinical trials in more than 100
countries to help customers deliver life-changing therapies to
improve health. We apply innovative technologies, therapeutic
expertise and a firm commitment to quality to bend the cost and
time curve of drug development and optimize value. For more
information, visit www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the proposed merger of
PPD by Thermo Fisher Scientific Inc.; and other factors disclosed
under the “Risk Factors” section in our periodic reports filed with
the Securities and Exchange Commission (SEC), including our latest
Annual Report on Form 10-K and Quarterly Report on form 10-Q, which
are available on our website at https://investors.ppd.com or the
SEC’s website at www.sec.gov. We assume no obligation and disclaim
any duty to revise or update any forward-looking statements, or
make any new forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211202005594/en/
PPD Contacts Media: Randy Buckwalter +1 919 456 4425
media@ppd.com Investors: Tracy Krumme +1 910 558 4186
investors@ppd.com
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Aug 2023 to Aug 2024